S&P 500   3,970.79 (+0.56%)
DOW   32,244.04 (+0.43%)
QQQ   309.82 (+0.02%)
AAPL   159.53 (+0.38%)
MSFT   279.16 (+0.54%)
META   205.54 (+0.62%)
GOOGL   104.99 (-0.58%)
AMZN   97.85 (-0.87%)
TSLA   190.23 (-1.04%)
NVDA   266.34 (-2.05%)
NIO   9.06 (-2.27%)
BABA   86.72 (+0.23%)
AMD   97.79 (-2.48%)
T   18.61 (+0.81%)
F   11.45 (+0.26%)
MU   60.73 (-0.99%)
CGC   1.92 (+0.26%)
GE   90.91 (-0.74%)
DIS   93.90 (-2.01%)
AMC   4.47 (+0.00%)
PFE   40.30 (+0.30%)
PYPL   73.42 (+1.19%)
NFLX   328.44 (+2.52%)
S&P 500   3,970.79 (+0.56%)
DOW   32,244.04 (+0.43%)
QQQ   309.82 (+0.02%)
AAPL   159.53 (+0.38%)
MSFT   279.16 (+0.54%)
META   205.54 (+0.62%)
GOOGL   104.99 (-0.58%)
AMZN   97.85 (-0.87%)
TSLA   190.23 (-1.04%)
NVDA   266.34 (-2.05%)
NIO   9.06 (-2.27%)
BABA   86.72 (+0.23%)
AMD   97.79 (-2.48%)
T   18.61 (+0.81%)
F   11.45 (+0.26%)
MU   60.73 (-0.99%)
CGC   1.92 (+0.26%)
GE   90.91 (-0.74%)
DIS   93.90 (-2.01%)
AMC   4.47 (+0.00%)
PFE   40.30 (+0.30%)
PYPL   73.42 (+1.19%)
NFLX   328.44 (+2.52%)
S&P 500   3,970.79 (+0.56%)
DOW   32,244.04 (+0.43%)
QQQ   309.82 (+0.02%)
AAPL   159.53 (+0.38%)
MSFT   279.16 (+0.54%)
META   205.54 (+0.62%)
GOOGL   104.99 (-0.58%)
AMZN   97.85 (-0.87%)
TSLA   190.23 (-1.04%)
NVDA   266.34 (-2.05%)
NIO   9.06 (-2.27%)
BABA   86.72 (+0.23%)
AMD   97.79 (-2.48%)
T   18.61 (+0.81%)
F   11.45 (+0.26%)
MU   60.73 (-0.99%)
CGC   1.92 (+0.26%)
GE   90.91 (-0.74%)
DIS   93.90 (-2.01%)
AMC   4.47 (+0.00%)
PFE   40.30 (+0.30%)
PYPL   73.42 (+1.19%)
NFLX   328.44 (+2.52%)
S&P 500   3,970.79 (+0.56%)
DOW   32,244.04 (+0.43%)
QQQ   309.82 (+0.02%)
AAPL   159.53 (+0.38%)
MSFT   279.16 (+0.54%)
META   205.54 (+0.62%)
GOOGL   104.99 (-0.58%)
AMZN   97.85 (-0.87%)
TSLA   190.23 (-1.04%)
NVDA   266.34 (-2.05%)
NIO   9.06 (-2.27%)
BABA   86.72 (+0.23%)
AMD   97.79 (-2.48%)
T   18.61 (+0.81%)
F   11.45 (+0.26%)
MU   60.73 (-0.99%)
CGC   1.92 (+0.26%)
GE   90.91 (-0.74%)
DIS   93.90 (-2.01%)
AMC   4.47 (+0.00%)
PFE   40.30 (+0.30%)
PYPL   73.42 (+1.19%)
NFLX   328.44 (+2.52%)
LON:SLN

Silence Therapeutics - SLN Share Forecast, Price & News

Add
Compare
Today's Range
N/A
50-Day Range
535
535
52-Week Range
N/A
Volume
913,528 shs
Average Volume
80,100 shs
Market Capitalization
£480.35 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

SLN stock logo

About Silence Therapeutics (LON:SLN) Stock

Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development of novel ribonucleic acid (RNA) therapeutics in hematology, cardiovascular, and other rare and metabolic indications. The company's platform includes mRNAi GalNAc Oligonucleotide Discovery platform designed to accurately target specific disease-associated genes in the liver. It designs short interfering RNA molecules to harness the body's natural mechanism of RNA interference, and degrading messenger RNA molecules that encode specific targeted disease-associated proteins in a cell. The company is developing various product candidates, including SLN360, which is Phase I clinical trials for the treatment of cardiovascular disease with high lipoprotein; SLN124 that is in Phase I clinical trials for the treatment of non-transfusion dependent thalassemia, and Phase Ib clinical trials for the treatment of myelodysplastic syndrome; and SLN500 for the treatment of complement-mediated diseases. It has a collaboration agreements with AstraZeneca to discover, develop, and commercialize small interfering RNA therapeutics for the treatment of cardiovascular, renal, metabolic, and respiratory diseases; and Mallinckrodt Pharma IP Trading DAC to develop and commercialize RNAi drug targets designed to silence the complement cascade in complement-mediated disorders. The company was formerly known as SR Pharma plc and changed its name to Silence Therapeutics plc in May 2007. Silence Therapeutics plc is headquartered in London, the United Kingdom.

Receive SLN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Silence Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

SLN Stock News Headlines

Buy THIS stock before Taiwan is attacked
... If the United States goes to war with another nuclear armed superpower, this could have a devastating impact on your retirement portfolio. Now, even Taiwan's own foreign minister is saying that China is on the cusp of a full scale invasion. But the good news is, if China invades Taiwan, there is a way to protect yourself.
The gold catalyst we’ve waited for
If you thought the SVB meltdown was bad… watch out. Because even bigger red flag just appeared. This signal proves that a recession is likely right around the corner. It will take most by surprise. Stocks will crash. Millions will go jobless, and lose their homes. But there is ONE important step you should take today to make sure you come out the other side OK.
Silence Therapeutics PLC ADR
Silence Therapeutics Begins Exclusive Nasdaq Trading
Silence Therapeutics : Update on AIM Delisting
See More Headlines
Receive SLN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Silence Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

SLN Company Calendar

Last Earnings
9/14/2020
Today
3/24/2023

Industry, Sector and Symbol

Industry
Biotechnology
Sub-Industry
N/A
Sector
Medical
CIK
N/A
Fax
N/A
Employees
74
Year Founded
N/A

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
£11.35 million
Cash Flow
GBX 84.41 per share
Book Value
GBX 18.20 per share

Miscellaneous

Free Float
N/A
Market Cap
£480.35 million
Optionable
Not Optionable
Beta
N/A

Key Executives

  • Mr. Mark Andrew Rothera (Age 58)
    Pres, CEO & Exec. Director
    Comp: $521.23k
  • Dr. Giles V. Campion M.D. (Age 67)
    Exec. VP, Head of R&D, Chief Medical Officer and Exec. Director
    Comp: $436.2k
  • Mr. Craig A. Tooman M.B.A. (Age 55)
    MBA, Chief Financial Officer
  • Ms. Gem Gokmen Hopkins
    Head of IR & Corp. Communications
  • Dr. Barbara A. Ruskin (Age 61)
    Sr. VP, Gen. Counsel & Chief Patent Officer
  • Ms. Linnea Elrington
    VP & Head of HR
  • Dr. John Strafford
    VP & Head of Bus. Devel.
  • Mr. Jørgen Wittendorff
    Sr. VP & Head of Manufacturing
  • Dr. Marie Wikstrom Lindholm Ph.D.
    Sr. VP & Head of Molecular Design













SLN Stock - Frequently Asked Questions

How have SLN shares performed in 2023?

Silence Therapeutics' stock was trading at GBX 535 at the beginning of the year. Since then, SLN shares have increased by 0.0% and is now trading at GBX 535.
View the best growth stocks for 2023 here
.

How were Silence Therapeutics' earnings last quarter?

Silence Therapeutics plc (LON:SLN) released its quarterly earnings data on Monday, September, 14th. The company reported ($13.70) earnings per share for the quarter, topping analysts' consensus estimates of ($21.70) by $8.00.

What other stocks do shareholders of Silence Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Silence Therapeutics investors own include Arch Therapeutics (ARTH), QuickLogic (QUIK), Asiamet Resources (ARS), ArcBest (ARCB), American Renal Associates (ARA), Apergy (APY), Anchiano Therapeutics (ANCN), Aileron Therapeutics (ALRN), Alkermes (ALKS) and Alfa Financial Software (ALFA).

What is Silence Therapeutics' stock symbol?

Silence Therapeutics trades on the London Stock Exchange (LON) under the ticker symbol "SLN."

How do I buy shares of Silence Therapeutics?

Shares of SLN stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.

What is Silence Therapeutics' stock price today?

One share of SLN stock can currently be purchased for approximately GBX 535.

How much money does Silence Therapeutics make?

Silence Therapeutics (LON:SLN) has a market capitalization of £480.35 million and generates £11.35 million in revenue each year.

How can I contact Silence Therapeutics?

Silence Therapeutics' mailing address is 72 Hammersmith Road, LONDON, W14 8TH, United Kingdom. The official website for the company is www.silence-therapeutics.com. The company can be reached via phone at +44-20-34576900.

This page (LON:SLN) was last updated on 3/24/2023 by MarketBeat.com Staff